Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Kun Fang; Guoqiang Dong; Hongyu Wang; Shipeng He; Shanchao Wu; Wei Wang; Chunquan Sheng

doi:10.1002/cmdc.201700666

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Kun Fang, Guoqiang Dong, Hongyu Wang, Shipeng He, Shanchao Wu, Wei Wang, Chunquan Sheng

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

Original language	English (US)
Pages (from-to)	30-36
Number of pages	7
Journal	ChemMedChem
Volume	13
Issue number	1
DOIs	https://doi.org/10.1002/cmdc.201700666
State	Published - Jan 8 2018
Externally published	Yes

Keywords

IDO1
antitumor activity
cancer immunotherapy
multitarget drug design

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Drug Discovery
Pharmacology, Toxicology and Pharmaceutics(all)
Organic Chemistry

Access to Document

10.1002/cmdc.201700666

Cite this

@article{4a2b1e1e50c54352bb12b26d5b37bd9b,

title = "Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA",

abstract = "Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.",

keywords = "IDO1, antitumor activity, cancer immunotherapy, multitarget drug design",

author = "Kun Fang and Guoqiang Dong and Hongyu Wang and Shipeng He and Shanchao Wu and Wei Wang and Chunquan Sheng",

note = "Funding Information: This work was supported by the National Key R&D Program of China (2017YFA0506000 to C.S.) and the National Natural Science Foundation of China (21738002 to W.W. and C.S., and 81725020 to C.S.). Publisher Copyright: {\textcopyright} 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim",

year = "2018",

month = jan,

day = "8",

doi = "10.1002/cmdc.201700666",

language = "English (US)",

volume = "13",

pages = "30--36",

journal = "ChemMedChem",

issn = "1860-7179",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

AU - Fang, Kun

AU - Dong, Guoqiang

AU - Wang, Hongyu

AU - He, Shipeng

AU - Wu, Shanchao

AU - Wang, Wei

AU - Sheng, Chunquan

N1 - Funding Information: This work was supported by the National Key R&D Program of China (2017YFA0506000 to C.S.) and the National Natural Science Foundation of China (21738002 to W.W. and C.S., and 81725020 to C.S.). Publisher Copyright: © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

PY - 2018/1/8

Y1 - 2018/1/8

N2 - Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

AB - Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

KW - IDO1

KW - antitumor activity

KW - cancer immunotherapy

KW - multitarget drug design

UR - http://www.scopus.com/inward/record.url?scp=85038092716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038092716&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201700666

DO - 10.1002/cmdc.201700666

M3 - Article

C2 - 29205945

AN - SCOPUS:85038092716

SN - 1860-7179

VL - 13

SP - 30

EP - 36

JO - ChemMedChem

JF - ChemMedChem

IS - 1

ER -

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this